- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00381875
Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV
A Pilot Study to Investigate the Safety and Immunogenicity of a Peptide Vaccine for HIV Infected HLA-A2 Individuals Designed to Impede the Development of Antiretroviral Resistance
RATIONALE: Vaccines made from peptides may help the body build an effective immune response. Incomplete Freund's adjuvant may stimulate the immune system in different ways and may help the vaccine work better. Colony-stimulating factors, such as GM-CSF, may increase the number of immune cells found in bone marrow or peripheral blood. Giving vaccine therapy together with incomplete Freund's adjuvant and GM-CSF may be an effective treatment for patients with HIV.
PURPOSE: This clinical trial is studying how well giving vaccine therapy together with incomplete Freund's adjuvant and GM-CSF works in treating patients with HIV.
Study Overview
Status
Conditions
Detailed Description
OBJECTIVES:
Primary
- Assess the safety of vaccination comprising E1M184V peptide with incomplete Freund's adjuvant in combination with sargramostim (GM-CSF) in patients with HIV who are HLA-A2 positive.
- Assess, preliminarily, the ability of E1M184V peptide vaccine to induce a cytotoxic T-cell response, defined by ELISPOT assay, in these patients.
Secondary
- Explore, preliminarily, the effect of this regimen on HIV viral load and CD4 count in these patients.
- Explore, preliminarily, the development of lamivudine or emtricitabine resistance in patients who subsequently receive lamivudine or emtricitabine.
- Explore, preliminarily, the ability of E1M184V peptide vaccine to induce a cytotoxic T-cell response as assessed by HLA-A2 class I tetramers and intracellular interferon gamma production after stimulation with E1M184V.
OUTLINE: This is a pilot study.
Patients receive vaccination comprising E1M184V peptide and incomplete Freund's adjuvant subcutaneously (SC) on day 1 in weeks 0, 4, 8, 12, and 16. Patients also receive sargramostim (GM-CSF) SC immediately after vaccination and once daily on days 1-4. Some patients do not receive GM-CSF after the first 2 doses of vaccine. Treatment continues in the absence of unacceptable toxicity.
Patients undergo blood collection at baseline and at 4, 12, 20, 36, and 52 weeks for biomarker/laboratory analysis. Assays may include immunoenzyme techniques and viral genotyping.
After completion of study treatment, patients are followed periodically for up to 2 years.
PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892-1182
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
- HIV-1 infection confirmed by Western blot and enzyme-linked immunosorbent assay
- HLA-A2 positive by polymerase chain reaction-sequence specific primers
- CD4 T-cell count ≥ 300/mm³
Must be receiving stable regimen of highly active antiretroviral therapy (HAART) that does not include lamivudine or emtricitabine for ≥ 1 month prior to study entry
- Patients on HAART, including lamivudine or emtricitabine, for which there is a medically appropriate regimen that does not include lamivudine or emtricitabine, are eligible if willing to change antiretrovirals
- Viral load < 50 copies/mL for 1 month prior to study entry
PATIENT CHARACTERISTICS:
- See Disease Characteristics
- ECOG performance status 0-1
- Life expectancy ≥ 6 months
- Hemoglobin ≥ 9 g/dL
- WBC ≥ 1,000/mm³
- Absolute neutrophil count ≥ 750/mm³
- Platelet count ≥ 75,000/mm³
- PT and PTT ≤ 120% of control unless lupus anticoagulant detected
- Bilirubin ≤ 1.5 times upper limit of normal (ULN) (≤ 7.5 mg/dL with direct fraction ≤ 0.7 mg/dL if on protease inhibitor therapy or due to Gilbert's syndrome)
- AST and ALT ≤ 2.5 times ULN
- Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
No hepatitis B surface antigen (HBsAg) or a prior history of HBsAg while on lamivudine or emtricitabine
- Prior treatment with tenofovir and currently HBsAg negative allowed
- No evidence of a severe or life-threatening infection other than HIV within the past 6 months
- No opportunistic infections requiring systemic therapy within the past month
- No active malignancy, except for basal cell carcinoma
- No known hypersensitivity to incomplete Freund's adjuvant or incomplete Freund's adjuvant VG (vegetable-grade), E1M184V peptide, or sargramostim (GM-CSF)
No other abnormality that would be scored as ≥ grade 3 toxicity, except any of the following (if asymptomatic):
- Hyperuricemia of grade 4 (without physiologic consequences)
- Elevation of lactate dehydrogenase ≥ grade 3
- Elevation of creatine phosphokinase (CPK) ≥ grade 3
- Hypophosphatemia ≥ grade 3 (if patient is on tenofovir)
- Elevation of alkaline phosphate of grade 3
Hyperamylasemia of ≥ grade 3 allowed if any of the following criteria are met:
- Macroamylasemia
- Lipase ≤ 2 times ULN
- Lymphopenia grade 3
- No other condition that, in the opinion of the investigator, would preclude compliance with study requirements
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
No systemic corticosteroids within the past 3 weeks
- Concurrent systemic corticosteroids allowed in the short term only
- Physiologic replacement doses of steroids allowed
- No prior vaccination with a vaccine that includes all or part of the reverse transcriptase of HIV-1
- No other concurrent investigational drugs or vaccinations
- No concurrent lamivudine or emtricitabine
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Impact of treatment on immune response, in terms of the difference between cytotoxic T-lymphocyte effector frequency, as measured by enzyme-linked immunospot (ELISPOT) at baseline and at week 20
|
Secondary Outcome Measures
Outcome Measure |
---|
Effects of treatment on viral load
|
Sequencing of any resultant HIV strains
|
CD4 counts for assessment of effects on HIV disease
|
Collaborators and Investigators
Collaborators
Investigators
- Kathleen M. Wyvill, BSN, RN, NCI - HIV and AIDS Malignancy Branch
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 060211
- NCI-P6066
- 06-C-0211
- NCI-6958
- CDR0000495768
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nonneoplastic Condition
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedNonneoplastic ConditionUnited States
-
Children's Cancer and Leukaemia GroupUnknownNonneoplastic ConditionUnited Kingdom
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCCompletedPrecancerous Condition | Nonneoplastic ConditionUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedLymphoma | Nonneoplastic ConditionUnited States
-
University Hospital BirminghamUnknownGraft Versus Host Disease | Nonneoplastic ConditionUnited Kingdom
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCTerminatedLymphoma | Nonneoplastic ConditionUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedLymphoma | Nonneoplastic Condition
-
Jonsson Comprehensive Cancer CenterCompletedPrecancerous Condition | Anal Cancer | Nonneoplastic ConditionUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); The Emmes Company, LLCCompletedLymphoma | Nonneoplastic ConditionUnited States
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCCompletedPrecancerous Condition | Anal Cancer | Nonneoplastic Condition | Neoplasm of Uncertain Malignant PotentialUnited States
Clinical Trials on immunoenzyme technique
-
Barbara Ann Karmanos Cancer InstituteNational Cancer Institute (NCI)TerminatedMultiple Myeloma and Plasma Cell NeoplasmUnited States
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Active, not recruitingBreast CancerUnited States
-
Roswell Park Cancer InstituteWithdrawnHealthy, no Evidence of Disease
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Terminated
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedProstate Cancer | Precancerous ConditionUnited States
-
Centre Oscar LambretUnknownBreast Cancer | Brain and Central Nervous System Tumors | Metastatic CancerFrance
-
Eastern Cooperative Oncology GroupNational Cancer Institute (NCI); SWOG Cancer Research NetworkCompletedLung CancerUnited States
-
University of ArizonaNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedMelanoma (Skin)